Medical/Pharmaceuticals
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
2024-03-06 19:33
3241
American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya
Project will combat infant mortality rates and lessen fetal distress in East Africa TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City S...
2024-03-06 18:48
3416
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC
HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...
2024-03-06 18:07
2727
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision
Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment ofMark W...
2024-03-06 12:29
2887
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...
2024-03-06 08:59
3875
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the fu...
2024-03-06 08:59
3643
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma
The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its op...
2024-03-06 08:45
2350
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...
2024-03-06 08:30
3032
Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024
* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...
2024-03-06 05:30
2671
Datasea Expects Approximately 1,128% Revenue Growth in 2024
BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...
2024-03-05 23:45
3699
Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production
IRVINE, Calif., March 5, 2024 /PRNewswire/ -- In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A ( PureRec RNase A), a challenge that persisted for over half a century. This breakthroug...
2024-03-05 22:00
2020
DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador
Expansion would make DaVita the largest dialysis services provider in Latin America DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations inBrazil and ...
2024-03-05 22:00
4582
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
GAITHERSBURG, Md., March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2024-03-05 21:00
3511
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environ...
2024-03-05 21:00
2609
IRBM Expands Global Reach in Drug Discovery with New Boston Office
Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...
2024-03-05 20:24
3032
One Million Global Healthcare Seekers Embrace MedicalTourism.com: Medical Tourism Magazine Leads the Way
WEST PALM BEACH, Fla., March 5, 2024 /PRNewswire/ -- Launched in 2023 by The Medical Tourism Association, DarwinAI (Artificial Intelligence) is an AI-enabled marketing technology revolutionizing the medical tourism landscape. Darwin AI uses powerful AI-enabled algorithms to drive brand awareness,...
2024-03-05 16:00
2375
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2024-03-05 13:35
3675
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...
2024-03-05 10:08
2762
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...
2024-03-05 07:01
2702
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
TAIPEI, March 4, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-opera...
2024-03-05 06:55
2735
Week's Top Stories
Most Reposted
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 307 media titles]
2026-04-01 09:00
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 304 media titles]
2026-04-06 10:00
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 302 media titles]
2026-03-31 13:53
Most Read
NYSE Content Update: Versigent To Ring Opening Bell As its Shares Debut for Trade
2026-04-01 22:44
5711
